恶性肿瘤患者血清磷酸葡萄糖异构酶活性测定的临床意义

Clinical significance on serum glucose phosphate isomerase determination of patients with malignant disease

  • 摘要: 本文对4组共300人的血清磷酸葡萄糖异构酶(GPI)活性和癌胚抗原(CEA)同时进行了测定,结果肺癌组、其它恶性肿瘤组患者的血清GPI活性显著高于健康对照组和肺良性疾病组。肺癌组的阳性率为66.7%,其它恶性肿瘤组的阳性率为49.5%;肺癌中以小细胞癌和腺鳞癌的阳性率为高,达80%以上,消化系肿瘤中以肝胆胰恶性肿瘤的阳性率较高,达78%以上。GPI活性的敏感度高于CEA,而CEA的特异性高于GPI,两者联合应用,可提高肺癌患者的诊断效率和正确诊断率。文章对GPI活性作为肺癌标记物的地位和临床应用价值进行了讨论,认为血清GPI活性的测定方法简便,可靠和价廉,值得今后在临床上推广应用。

     

    Abstract: It was measured that serum glucose phosphate isomerase (GPI) activity and carcinoembryonic antigen (CEA) of 300 subjects, which were divided into 4 groups at the same time. Serum GPI and CEA were significantly higher in patients with lung cancer and malignant diseases than those in the control group of healthy subjects and the benign diseases group. A 66.7% positive rate in the lung cancer group and 49.5% in other malignant disease groups were reported, respectively. The positive rates in small cell lung cancer and squamous cell lung cancer were more than 80%, especially. GPI sensitivity was higher than CEA, and CEA specificity was higher than GPI. The diagnostic efficiency and correct diagnostic rate can be increased by combining both. Evaluating GPI as a lung cancer marker was discussed.

     

/

返回文章
返回